This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Heart Failure Hospital Preserved Ejection Fraction 
DAIC
MAY 6, 2024
Initially discovered and developed by Orion Corporation in Finland, intravenous levosimendan is approved in 60 countries outside the United States for use in hospitalized patients with acutely decompensated heart failure. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,
Medical Xpress - Cardiology
JULY 29, 2024
A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
The British Journal of Cardiology
JANUARY 14, 2025
Heart failure (HF) is a significant problem in the UK with variation in services across the country. Seventy-nine responses describing hospital-based HF services from all devolved countries were received. The clinical lead in 82% of hospitals was a cardiologist with specialist interest in HF. and 75%, respectively.
DAIC
JULY 31, 2024
mtaschetta-millane Wed, 07/31/2024 - 06:00 July 31, 2024 — A novel study co-authored by a heart failure cardiologist at University Hospitals Harrington Heart & Vascular Institute, demonstrates the effectiveness of a newly developed scoring system in identifying patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
111 JAMA Cardiology
NOVEMBER 17, 2024
This cohort study evaluated adoption rates of sodium-glucose cotransporter-2 inhibitors at US hospitals for patients with heart failure and mildly reduced or preserved left ventribular ejection fraction.
DAIC
JUNE 21, 2024
announced that the peer-reviewed Journal of the American College of Cardiology: Heart Failure has published a research paper concluding that INPEFA (sotagliflozin) is cost-effective for people with diabetes and recent worsening heart failure using commonly accepted willingness-to-pay thresholds. “Our healthcare system.
105 
DAIC
JUNE 4, 2024
American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.
European Journal of Heart Failure
NOVEMBER 29, 2023
ABSTRACT Aims Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.
Circulation
JANUARY 22, 2025
Circulation, Ahead of Print. Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation.
European Journal of Heart Failure
OCTOBER 30, 2023
In patients with heart failure with preserved ejection fraction (HFpEF), abnormal global longitudinal strain (GLS) is a strong predictor for clinical events and can help identity patients who are at risk for future decline in left ventricular ejection fraction (LVEF). After a median follow-up of 4.6 years,
Circulation
NOVEMBER 11, 2024
As heart failure with preserved ejection fraction (HFpEF) comprises half of all heart failure cases, understanding its management and effect on outcomes is crucial. Multivariate logistic and linear regression analyses were performed, adjusting for multiple patient and hospital confounders.
Journal of Cardiovascular Electrophysiology
DECEMBER 17, 2024
Abstract Background Heart failure (HF) with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are associated with high morbidity and mortality. HFpEF were defined as HFA-PEFF score of 5 or 6 and left ventricular ejection fraction 50% before the initial CA. 423 by a log-rank test).
Journal of Cardiovascular Electrophysiology
FEBRUARY 13, 2024
Abstract Introduction Heart failure (HF) and atrial fibrillation (AF) frequently co-exist. Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF).
European Journal of Heart Failure
MARCH 4, 2024
Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Empagliflozin reduced the risk of lower respiratory tract infections. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide.
JAMA Cardiology
SEPTEMBER 30, 2021
This cohort study examines the prevalence of epicardial coronary artery disease and coronary microvascular dysfunction in hospitalized patients with heart failure with preserved ejection fraction.
Frontiers in Cardiovascular Medicine
OCTOBER 10, 2024
ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heart failure (HF).MethodsFrom Patients diagnosed with preserved ejection fraction (HFpEF) were treated with Vericiguat combined with “ARNI, BB, SGLT2i” therapy.
HeartRhythm
APRIL 30, 2024
Previous studies have demonstrated significant morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), particularly with accompanying atrial fibrillation (AF).
European Journal of Heart Failure
MARCH 30, 2025
Metabolic dysfunction and incident heart failure. Aims The extent to which metabolic syndrome (MetS) severity influences subclinical myocardial remodelling, heart failure (HF) incidence and subtypes, remains unclear. CI, confidence interval; MetS, metabolic syndrome.
European Journal of Heart Failure
FEBRUARY 5, 2025
Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. Abstract Aims Angiotensin receptorneprilysin inhibitor (ARNI) has played an increasingly important role in the management of heart failure (HF).
HeartRhythm
APRIL 30, 2024
Atrial fibrillation (AF) with comorbid heart failure with preserved ejection fraction (HFpEF) presents a significant management challenge. While the association between AF and heart failure with reduced ejection fraction is extensively studied, the correlation between AF and HFpEF remains less explored.
Journal of the American Heart Association
JANUARY 19, 2024
BackgroundSystemic chronic inflammation plays a role in the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction‐associated fatty liver disease. The study outcome was time to the first hospitalization for HF. In 10 019 middle‐aged individuals (mean age, 63.3±10.6
Circulation
NOVEMBER 11, 2024
Left ventricular ejection fractions were similar in both MAC (58.3 + 11.9) Conclusion:Among patients hospitalized with ‘diastolic heart failure’ MAC is associated with worse cardiovascular outcomes. vs non-MAC (58.2 + 12.6). Median follow-up was 423 days (MAC group) and 575 days (non-MAC group).
DAIC
JANUARY 23, 2024
Getty Images milla1cf Tue, 01/23/2024 - 13:38 January 23, 2024 — Sequana Medical NV , a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announced that an independent Data and Safety Monitoring Board (DSMB) approved the start of the randomized cohort in MOJAVE , the US Phase 1/2a study of DSR 2.0
104 HeartRhythm
JUNE 23, 2024
Furthermore, among patients with heart failure, both reduced and preserved ejection fraction, catheter ablation reduces heart failure hospitalizations and mortality.1-10
JAMA Cardiology
JULY 23, 2024
Among patients with heart failure with preserved ejection fraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.
DAIC
MARCH 26, 2025
Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).
Frontiers in Cardiovascular Medicine
FEBRUARY 6, 2025
However, the relationship between PWR and adverse outcomes in patients with acute decompensated heart failure (ADHF) remains unclear. The primary outcome measure was all-cause mortality within 30 days of hospitalization. vs. 0.87, P for interaction=0.0067).ConclusionThis vs. 0.87, P for interaction=0.0067).ConclusionThis
Science Daily - Heart Disease
SEPTEMBER 2, 2024
Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial.
DAIC
APRIL 2, 2024
Yakubu Bene-Alhasan, MD milla1cf Tue, 04/02/2024 - 12:14 April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heart failure.
105 European Journal of Heart Failure
DECEMBER 13, 2023
BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes.
Journal of the American Heart Association
DECEMBER 14, 2024
The main outcome was the composite of allcause mortality and first HF hospitalization. The mean age, body mass index, left ventricular ejection fraction, and EAT volume were 57.0 During a median followup of 34 months, 169 patients (24.4%) died or were hospitalized for HF. Of 692 participants, 41.3% were women.
DAIC
FEBRUARY 22, 2024
The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heart failure, is funded by a five-year, $30 million grant , awarded to Wake Forest University School of Medicine in 2022 by the National Institute of Aging, part of the National Institutes of Health.
105 European Journal of Heart Failure
DECEMBER 19, 2024
BNP, B-type natriuretic peptide; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EP, endpoint; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SwedeHF, Swedish Heart Failure Registry; US, United States.
European Journal of Heart Failure
DECEMBER 7, 2023
ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preserved ejection fraction (HFpEF). 2.92, p = 0.01).
European Journal of Heart Failure
DECEMBER 15, 2024
A summary of effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum. The primary composite outcome was total HF hospitalizations and cardiovascular (CV) death.
DAIC
APRIL 6, 2024
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
Journal of Cardiovascular Electrophysiology
OCTOBER 21, 2024
Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preserved ejection fraction (HFpEF). The primary endpoint was a composite of death from any cause or hospitalization for worsening HF.
European Journal of Heart Failure
FEBRUARY 5, 2025
Beta-blockers are commonly used in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER).
DAIC
APRIL 6, 2024
The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).
European Journal of Heart Failure
FEBRUARY 18, 2024
Global longitudinal strain (GLS) and clinical outcomes in heart failure with preserved ejection fraction (HFpEF). Almost 47% of patients with HFpEF had evidence of left ventricular (LV) subclinical dysfunction, defined as absolute LV GLS 0.1).
Science Daily - Heart Disease
MARCH 26, 2025
Compared with those who spent most of their time in a single room, people with heart failure with preserved ejection fraction (HFpEF) who were able to travel outside of their home without assistance were significantly less likely to be hospitalized or die within a year, according to a new study.
European Journal of Heart Failure
NOVEMBER 3, 2024
Abstract Aims Atrial fibrillation (AF) is common in heart failure (HF) and negatively impacts outcomes. The role of ablation-based rhythm control in patients with AF and HF with preserved (HFpEF) or mildly reduced ejection fraction (HFmrEF) is not known.
CardiacWire
APRIL 26, 2024
Statins are one of the most-prescribed drug classes in the world, but there’s still little data on their heart failure benefits, especially for HFpEF patients. The two major RCTs evaluating statins as a heart failure treatment (CORONA and GISSI-HF) didn’t show significant benefits, although they mainly focused on HFrEF patients.
104 
Medical Xpress - Cardiology
MARCH 25, 2025
The findings underscore the value of supporting holistic care and encouraging people with heart failure to maintain an active lifestyle and engage with others in their community to the extent possible, researchers said.
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content